Form 4: Mural Oncology CEO Sells Shares to Cover Tax Obligations Under Pre-Arranged Plan

Mural Oncology plc's CEO, Caroline Loew, sold 12,531 ordinary shares on July 7, 2025, at a weighted average price of $2.432 per share to satisfy tax withholding obligations related to vested restricted stock units.

Summary

• Caroline Loew, Chief Executive Officer and Director of Mural Oncology plc (MURA), reported a transaction involving the company's ordinary shares.
• On July 7, 2025, a total of 12,531 ordinary shares were sold.
• The shares were sold at a weighted average price of $2.432 per share, with individual transaction prices ranging from $2.43 to $2.53.
• The sale was an automatic, non-discretionary transaction executed to satisfy tax withholding obligations associated with the vesting of restricted stock units (RSUs) that were granted to Ms. Loew on December 14, 2023.
• This automatic sale was pre-arranged and provided for in a restricted stock unit agreement, consistent with an affirmative defense to liability under Rule 10b5-1, which was entered into on March 27, 2024.
• Following this transaction, Caroline Loew beneficially owns 293,059 ordinary shares, which includes 220,148 restricted stock units.

Sentiment

Score: 7

Explanation: The transaction is a non-discretionary sale for tax purposes, which is a routine event for executives receiving equity compensation and is generally viewed as neutral. The existence of a Rule 10b5-1 plan adds a layer of transparency and pre-planning, which is a positive governance indicator.

Positives

• The sale was non-discretionary, executed automatically to satisfy tax withholding obligations, indicating it was not a market-timing decision by the CEO.
• The transaction was pre-arranged under a Rule 10b5-1 plan, demonstrating a structured and transparent approach to equity compensation management and adherence to corporate governance best practices.

Negatives

• No direct negatives are indicated as the sale was for tax purposes and not a discretionary divestment.

Risks

• NA

Future Outlook

NA

Management Comments

• "Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 14, 2023."
• "The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement that includes a 'binding contract' consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on March 27, 2024, and the sale does not represent a discretionary trade by the Reporting Person."
• "The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.43 to $2.53. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."

Industry Context

This Form 4 details a routine insider transaction for tax purposes, which is common across all industries for executives receiving equity compensation. It does not provide specific insights into broader industry trends for oncology or biotechnology.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: The sale represents a minor, routine dilution of shares, but it is a non-discretionary transaction for tax purposes, not indicative of a lack of confidence from management. The use of a Rule 10b5-1 plan provides transparency regarding the nature of the sale.
• Employees: No direct impact on employees is indicated by this transaction.
• Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this transaction.

Next Steps

• NA

Key Dates

Recommendation

Keywords

Mural Oncology, MURA, Caroline Loew, CEO, Director, SEC Form 4, Insider Transaction, Share Sale, Restricted Stock Units, RSU, Tax Withholding, 10b5-1 Plan, Equity Compensation